Godavari Drugs Ltd

Godavari Drugs, a microcap in the Pharmaceuticals & Drugs sector, has faced significant volatility, hitting a new 52-week low. The stock has declined consecutively over six days, with a notable drop over the past year, contrasting with the overall positive performance of the Sensex.

Godavari Drugs has announced its financial results for the quarter ending December 2024, revealing a significant shift in its financial performance. The company's stock assessment has undergone a notable revision, indicating changes in its underlying financial metrics that may impact stakeholders' perspectives on its operational health.

Godavari Drugs, a microcap pharmaceutical company, has reported a flat performance in the second quarter of fiscal year 2024-2025. While the company's PAT has shown a growth of 62.87%, its Net Sales and Operating Profit have declined. Investors should carefully evaluate the company's financials before making any investment decisions.

Godavari Drugs, a microcap pharmaceutical company, has been downgraded to a 'Hold' by MarketsMOJO on October 22, 2024 due to concerns about its high debt to EBITDA ratio and decreasing stake of promoters. Despite positive financial performance and stock trends, caution is advised before investing in this company.

Godavari Drugs, a microcap pharmaceutical company, has been upgraded to a 'Buy' by MarketsMOJO on October 16, 2024, due to its positive results in June 2024. The stock has shown a significant improvement in its technical trend and is currently trading at an attractive valuation. However, there are some risks associated with its high debt and slow growth.

Godavari Drugs, a microcap pharmaceutical company, received a 'Hold' rating from MarketsMOJO on October 7th, 2024. Despite positive results and a bullish trend, concerns about long-term growth potential and high debt levels warrant a 'Hold' rating. The stock has attractive valuations and stable shareholders, but a low CAGR and high debt to EBITDA ratio.

Godavari Drugs, a microcap pharmaceutical company, has received a 'Buy' rating from MarketsMOJO after reporting positive results in June 2024. The stock is currently in a bullish range and has shown a 1.61% return since September 27, 2024. Attractive valuation and potential for growth make it a promising investment opportunity, but high debt and slow long-term growth should also be considered.

Godavari Drugs, a microcap pharmaceutical company, received a 'Hold' rating from MarketsMOJO on September 25, 2024. Despite positive results and multiple bullish factors, the company's high debt to EBITDA ratio and poor long-term growth may impact its financial stability. Investors should exercise caution before making any investment decisions.

Godavari Drugs, a leading pharmaceutical company in the microcap industry, has recently seen a surge in its stock price, reaching an all-time high on September 1st, 2024. This can be attributed to the company's strong financial performance and growth prospects, making it an attractive investment option. Despite a slight dip, the stock has remained volatile and consistently trading above its moving averages, indicating a positive trend in the market.

Despite some volatility, Godavari Drugs has consistently outperformed its sector and has shown strong growth potential in the past year.

Godavari Drugs, a leading pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on August 30, 2024. The stock has been performing well, outperforming the sector by 2.04% today. With a strong track record and positive performance, Godavari Drugs is a preferred choice for long-term investors.

Godavari Drugs, a leading pharmaceutical company in the microcap industry, has reached an all-time high stock price of Rs. 155 on August 30, 2024. With a 'Buy' call from MarketsMOJO and consistent upward trend, the stock has outperformed the sector by 0.91% and has shown a remarkable 49.68% increase in returns in the last 6 days. The company's stock is also trading higher than its moving averages and has outperformed the Sensex by 39.84% in the past year, showcasing its potential for growth and success in the future.

Godavari Drugs, a microcap pharmaceutical company, has been upgraded to a 'Buy' by MarketsMOJO on August 29, 2024, after reporting positive results in June 2024. The stock has shown significant improvement and is currently in a bullish range, with multiple bullish factors contributing to its success. With attractive valuation and market-beating performance, Godavari Drugs is a promising investment option in the pharma industry.

Godavari Drugs, a microcap pharmaceutical company, has reached a new milestone as its stock price hit a 52-week high on August 29, 2024. The stock has been performing well in the market, with a consecutive gain for the last 5 days and a rise of 44.34% in that period. According to MarketsMOJO, the stock call for Godavari Drugs is 'Hold' and it has been trading higher than various moving averages, indicating a positive trend. With a strong performance in the past year, the company continues to show promising potential in the market.

Godavari Drugs, a microcap pharmaceutical company, has gained attention in the stock market as its share price reached an all-time high of Rs.152 on August 29, 2024. With a 'Hold' recommendation from MarketsMOJO, the stock has outperformed the sector by 7.26% and gained 48.25% in the last 5 days. Its strong financial standing and positive trend make it a promising investment option.

Godavari Drugs, a microcap pharmaceutical company, has seen a surge in its stock price, reaching a 52-week high on August 28, 2024. With a 'Hold' recommendation from MarketsMOJO, the stock has outperformed the sector by 9.81% and is currently trading above its moving averages. Despite being a lesser-known company, Godavari Drugs has shown a strong 34.44% growth in the past year, indicating its potential for success in the pharmaceutical industry.

Godavari Drugs, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high on August 28th, 2024. The stock has outperformed the sector by 7.26% and has shown consecutive gains for the last 4 days, with a remarkable 36.78% increase. It is currently trading above its moving averages, indicating a positive trend and has outperformed the Sensex in the past year. With a 'Hold' rating from MarketsMOJO, Godavari Drugs is a promising stock in the pharma industry.

Godavari Drugs, a microcap pharmaceutical company, has been making headlines in the stock market with its share price reaching a 52-week high on August 27, 2024. The stock has outperformed the sector by 6.73% and has seen a consecutive gain of 17.65% in the last three days. It is currently trading higher than its moving averages and has shown a 1-year return of 13.55%. MarketsMOJO has given a 'Hold' call for the stock, indicating its promising potential in the pharmaceutical industry.

Godavari Drugs, a microcap pharmaceutical company, has seen a surge in its stock price, reaching an all-time high of Rs.123.8 on August 27, 2024. The company's stock has been performing well, outperforming the sector by 8.49% and trading higher than its moving averages. However, it is important to do thorough research before investing.